Utilizing a synergistic drug screening approach, we identified a novel drug combination targeting PI3K and P21-associated kinase (PAK), confirmed its efficacy in an animal model of NF2-related schwannomatosis, and explored the mechanism through which these inhibitors decreased mouse and human MD-SCs proliferation and survival. This evidence concerns the gene NF2 and schwannomatosis.